James A Hardin

Title: Innovations by James A Hardin

Introduction

James A Hardin is a notable inventor based in Calgary, Canada. He has made significant contributions to the field of gastrointestinal therapeutics. With a total of 2 patents, his work focuses on the application of epidermal growth factor (EGF) in treating various gastrointestinal conditions.

Latest Patents

James A Hardin's latest patents include a method of treating gastric ulcers through the administration of epidermal growth factor. This patent describes new utilities for EGF, particularly its effectiveness in preventing gastrointestinal colonization by pathogens. Another patent outlines the use of EGF as a gastrointestinal therapeutic agent. This method involves inhibiting or treating gastrointestinal colonization of pathogens in animals by administering EGF. Additionally, it describes a method for increasing weight gain in animals through oral administration of EGF, which can be included in their feed or drinking water. EGF proves to be beneficial in treating a wide range of intestinal infections, including enteric colibacillosis.

Career Highlights

James A Hardin is associated with University Technologies International, Inc., where he continues to innovate in the field of gastrointestinal health. His research has the potential to impact both veterinary and human medicine significantly.

Collaborations

Some of his notable coworkers include Andre Gerald Buret and D Grant Gall, who contribute to the collaborative efforts in his research endeavors.

Conclusion

James A Hardin's work exemplifies the importance of innovation in medical science, particularly in the treatment of gastrointestinal diseases. His patents reflect a commitment to improving health outcomes through scientific advancements.